Avenue Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATXI Nasdaq 2834 www.avenuetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avenue Therapeutics, Inc.

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Nov 14th, 2024 9:05 pm
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - Oct 9th, 2024 12:30 pm
Avenue Therapeutics to Participate in Upcoming Investor Conferences - Sep 3rd, 2024 12:30 pm
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Aug 13th, 2024 8:05 pm
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Aug 9th, 2024 8:05 pm
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - Jun 20th, 2024 12:30 pm
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - May 16th, 2024 12:30 pm
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - May 15th, 2024 12:30 pm
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds - Apr 29th, 2024 12:00 pm
Avenue Therapeutics Announces Reverse Stock Split - Apr 24th, 2024 11:30 am
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 - Mar 25th, 2024 12:30 pm
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - Mar 18th, 2024 8:05 pm
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - Mar 15th, 2024 12:15 pm
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting - Mar 11th, 2024 12:00 pm
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy - Feb 22nd, 2024 1:30 pm